Browsing Tag
Roche
85 posts
Vabysmo shows 4-year durability in wet AMD and 60% lesion clearance in PCV: What the new Genentech data reveals
Genentech’s Vabysmo shows four years of vision durability in AMD and strong lesion control in PCV—see what’s next for this bispecific breakthrough.
Foresight Diagnostics strikes licensing deal with Roche for PhasED-Seq in non-Hodgkin’s lymphoma
Foresight Diagnostics licenses PhasED-Seq to Roche for Non-Hodgkin’s Lymphoma diagnostics, settling litigation and boosting precision oncology prospects.
Alnylam Pharmaceuticals (NASDAQ: ALNY) to launch global Phase 3 trial of RNAi therapy zilebesiran in high-risk hypertension patients
Alnylam Pharmaceuticals (NASDAQ: ALNY) moves its RNAi drug zilebesiran into a global Phase 3 trial for hypertension after ESC 2025 data showed sustained blood pressure reductions.
Bio-Thera extends partnership with STADA to bring tocilizumab biosimilar across Europe
Bio-Thera and STADA extend alliance to bring tocilizumab biosimilar across Europe, expanding immunology access and reshaping the biosimilars market.
Genentech’s Columvi combo fails to secure FDA approval for second-line DLBCL use
FDA rejects Genentech’s sBLA for Columvi-GemOx in second-line DLBCL treatment; survival benefit data deemed insufficient for U.S. approval.
Why off-the-shelf CAR T therapies are attracting billion-dollar deals despite early-stage risks
Big pharma is betting billions on off-the-shelf CAR T therapies. Can allogeneic platforms overcome early-stage risks to transform cancer care?
Facioscapulohumeral muscular dystrophy market is set to expand through 2034 with gene therapy innovation and FDA acceleration
Facioscapulohumeral muscular dystrophy market to expand across 7MM by 2034, driven by gene therapy, rising diagnosis, and key drug launches from Roche, Avidity, and Epicrispr.
Why amylin is gaining pharma attention in obesity drug development: From amycretin to AZD6234
Discover how Novo Nordisk, AstraZeneca, and others are betting on amylin-based obesity drugs like amycretin and AZD6234 to reshape metabolic care.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
The business of AI in oncology: Who’s building the platforms hospitals trust?
Tempus, Guardant, Freenome, and Paige are building the AI oncology platforms hospitals now rely on. Discover the financials and future shaping cancer diagnostics.